The U.S. market for drugs that target constipation from opiods could grow almost tenfold by 2019.» Read More
What a crazy week, right? Monday, Amgen had a huge upside revenue and earnings surprise. Tuesday, the Food and Drug Administration issued its new restrictions on the use of Amgen's anemia drugs in certain cancer patients. Later that same day, Elan and Wyeth released the big Alzheimer's drug test results.
Shares in Irish drugmaker Elan dived more than 50 percent to their lowest level since 2005 on Friday as a second product setback in a week shattered confidence in its line-up of biotech medicines.
Novo Nordisk's diabetes drug might just send this stock much, much higher.
Biogen Idec and Elan notified regulators of two confirmed cases of a potentially deadly brain disease in multiple sclerosis (MS) patients being treated with Tysabri.
Bristol-Myers Squibb's proposal to buy ImClone Systems at $4.5 billion brings back memories of the Martha Stewart scandal that went beyond financial news headlines and made ImClone a household name.
I was told to leave the building immediately otherwise security would be called and it "would get ugly." That's a quote from an AA staffer. It didn't get ugly. We quickly packed up all our stuff and moved outside.
Drugmaker AstraZeneca, enjoying a favorable tailwind from currencies, lifted its full-year earnings forecast on Thursday as second-quarter results came in ahead of expectations.
European earnings were mixed Thursday, with telecoms reporting results in line or above forecasts, while energy companies and financials posted profit declines or figures below market expectations.
A new groundbreaking research that could potentially lead to cure Alzheimer's disease and on how Chesapeake's CEO hopes to move Americans away from "expensive imported oil" to natural gas. Following are today's top videos:
Baxter researchers unveiled positive mid-stage test results on an intravenous drug, Wednesday, which is already in late-stage development in a very small number of patients.
Inconclusive test results for a new Alzheimer's drug caused an unjustified sell-off in stocks for pharmaceutical companies Elan and Wyeth, said Elan CEO Kelly Martin.
When covering this beat you often have to become as fluent as possible in different disease jargon. But nothing could have prepared me for the alphabet soup served up in this highly anticipated release.
Keenly awaited details on Elan and Wyeth's new Alzheimer's drug bapineuzumab show it raised the risk of a potentially serious side effect, especially in people with a genetic risk of the disease, the companies said on Tuesday.
I'm at the International Conference on Alzheimer's Disease--aka ICAD--in Chicago where we're waiting for the highly anticipated detailed test results on the promising experimental drug from Wyeth and Elan.
Two strategists, Stephen Wood at Russell Investments and John Manley at Citi Smith Barney, shared their market rebound strategies with CNBC.
Amgen reported a profit and sales that climbed higher and beat analysts' forecasts as sales of two key drugs topped expectations.
Shares of Amgen surged after the company reported positive trial results for its osteoporosis drug candidate denosumab—which one analyst terms "a future blockbuster."
Amgen surprised the market late on a summer Friday by announcing positive test results from the big, crucial study of its experimental osteoporosis drug. The stock shot up after hours and continues to rally this morning.
Amgen shares leaped in late trading Friday after the company said a pivotal trial of its experimental osteoporosis drug denosumab met its goal of significantly reducing the risk of bone fracture in post-menopausal women.
Leerink Swann, which specializes in healthcare equities research, is out with a couple of noteworthy surveys--one on the collateral damage to Merck and Schering-Plough's Vytorin this week and the other on drug-coated stents from Abbott Labs, Boston Scientific, Johnson & Johnson and Medtronic.